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Introduction

Orbital Lesions

Treatment Process

Considerations

The purpose of the research done was to evaluate the use
of CyberKnife Stereotactic Radiosurgery (SRS) for
treating orbital lesions. Efficacy and tolerability of such
treatment was analyzed with data drawn from multiple
sources, regarding dose and fractionation, quality of life
following treatment(s) and prognosis. CyberKnife SRS is
the newest, most advanced model of radiation delivery
systems, featuring a robotic arm capable of manipulating
the linear accelerator into thousands of unique angles.
The addition of new angles allows for a more precise
concentration of radiation delivered to the lesions. In the
case of optic lesions, it is crucial to minimize dose to
adjacent structures such as optic nerve, lens and fovea.
CyberKnife SRS is superior for treatment in small
anatomical locations due to steep dose gradients and
target localization system, allowing maximum sparing of
organs at risk. While CyberKnife SRS is rapidly
becoming the gold standard for orbital lesions, there is
still a likelihood that other treatments may be required as
an adjunct therapy for treatment purposes. However,
current research identifies the high success rate of
CyberKnife SRS but acknowledges the need for further
research in dosage and fractionation.

•

Damage or abnormal change in tissue in or around
the orbit

•

Benefits

Cancer that has metastasized to the eye is more
common than a primary orbital cancer

•

CyberKnife Stereotactic Radiosurgery is:
• the newest type of stereotactic radiosurgery;
consisting of a 6-MV linear accelerator fixed on an
image-guided, computer-operated frameless robotic
arm
• 30 to 90 minutes per treatment
• used to treat lungs, pancreas, brain, head and neck,
spine and prostate cancers
(Long et al., 2019, p. 451)
Fig. 1
Fig. 2

•
•

(American Cancer Society, n.d.,)

Melanoma is the most prevalent eye cancer, with
uveal melanoma being the most frequent primary
intraocular tumor

(Klingenstein et al., 2016, p. 1005)

Types of Orbital Lesions

Daftari, I., 2009

CyberKnife room setup and patient in immobilization mask for treatment

• non-invasive and usually done in less than 5
fractions (days) at a high dose, with a more minimal
dose to surrounding tissue than conventional
radiotherapy
• proven superior by its specialized target spatial
localization system and steep dose gradient which
allow for maximum sparing of organs at risk
• image-guided which allows the robotic arm to track
patient movement within 0.5-10.0 mm and 1-3
degrees and remain aligned to the target area

T2- and contrast-enhanced T1-weighted MRI is
acquired (see Fig. 4)

•

The doctor, dosimetrist and physicist spend 30-40
minutes collaborating

•

The visible tumor is contoured as the target volume

•

Inverse treatment planning is done to create a steep
fall in dose outside the tumor volume

• Intraocular- within the orbit
•

The patient is positioned on the table with an
immobilization mask

•

The linear accelerator delivers 100-150 beams at
differing angles

Etiology

•

• Age, thyroid disorders, systemic lupus erythematous,
rheumatoid arthritis, fibro-inflammatory disorders,
sarcoidosis, and granulomatosis with polyangiitis

MR images are taken at each new angle to account
for position of tumor due to movement

•

The entire process is completed within 2.5 hours

• Periocular-surrounding the orbit (muscles & adnexa)
• Pseudotumor- swelling behind the orbit
• Primary or Metastasized

• Mean age: 65 +/- 10

• Uveal melanoma is rare, but the most common
cancer spread to the eye

Usually developed in the choroid, which has a
similar function to skin cells

Signs/Symptoms
• Blurred or decreased vision
Treatment plan using CT images, showing tumor volume and beam angles

Fig. 3

• Limited ocular motility

(Desideri et al., 2019, p. 2)

• Diplopia (double vision)

Dose & Fractionation

• Swelling

•

Treatments are non-isocentric

• Proptosis (protrusion)

•

Dose ranges on the size of the tumor and facility
preference

•

• Pain
• Redness

(Sasaki et al., 2021)

No standard recommendation for dose and
fractionation exists (see examples below)
•

Orbital cavernous hemangioma before & after

Treatment Options
Radiation Therapy treatment- CyberKnife,
GammaKnife, IMRT, Proton therapy,
Brachytherapy

17-22 Gy in one fraction with 12/39 patient
experiencing reoccurrence
(Desideri et al., 2019, p. 4)

•

15 Gy over 3 fractions with partial regression
after 12 months

•

15 Gy over 3 fractions with complete recovery
(Klingenstein et al., 2016, p. 1007)

•

19 patients treated with 24-35 Gy over 1-5
fractions with 75% overall response rate

•

13 patients treated with 13-22 Gy over 3-5
fractions with 100% overall response rate

Enucleation or surgical resection
(Klingenstein et al., 2016, p. 1005)

•

Systemic treatments- immunotherapy, hormonal
therapy, chemotherapy
(Riva et al., 2019, p. 65)

(Desideri et al., 2019, p.2-5)

• Short treatment length allows focus on other
procedures

(Riva et al., 2019, p. 65)

Risks
•

Orbital irradiation may lead to a wide spectrum of
acute and late toxicities such as: permanent
blindness, conjunctivitis, panophthalmitis, dry eye
syndrome, cataract, keratopathy, retinopathy,
neovascularization of the iris, and optic neuropathy
(Riva et al., 2019, p. 65)

•

Optic pathways and orbital adnexa are
radiosensitive periocular structures that are prone to
late toxicity
(Desideri et al., 2019, p.2)

•

In the long term, functional and cosmetic
disturbances may reduce quality of life

•

Primary lesion of the orbit 5-year survival rate: 85%

•

Metastasized 5-year survival rate: 71%

•

(American Cancer Society, n.d.,)

•

• Ideal for palliative treatment

Prognosis/Outcome

(Riva et al., 2019, p. 64)

•

• Delays the need for surgery or enucleation

(Yaprak et al., 2018, p.198)

• Orbital metastases could usually be associated with a
poor systemic prognosis

(Yaprak et al., 2018, p.198)

• Reduced tumor volume (size), offering immediate
symptom relief

(Klingenstein et al., 2016, p. 1007)
Fig. 4

• Epiphora (watering)
Yuan, Z., 2009

Retrotubular anesthesia is administered, achieving
akinesis for 2.5-3 hours

(Yaprak et al., 2018, p.199)

(American Cancer Society, n.d.,)

Most reported cases presented a monophasic
disease course, yet there was some reoccurrence

• Reoccurrence was more common among those
below mean age,
bilateral disease,
and/or partial
initial steroid
response
(Sasaki et al., 2021, p. 199)
Before & after treatment with CyberKnife (Riva et al., 2019, p. 65)

Conclusion
Most research points toward CyberKnife SRS as a
safe, efficient and effective treatment method for
orbital lesions. Currently, no recommendation exists
about correct doses and fractionations for this
treatment. These factors should be carefully planned
according to proximity of critical structures,
histology, and target lesion volume. Current research
suggests CyberKnife is a safe and effective course of
treatment. Further research must be conducted to
fully understand the most efficient planning of
treatment for orbital lesions using CyberKnife SRS.

